Legitimacy construction by Merck within the Brazilian innovation system
| Uncertainty trigger: societal | |||
|---|---|---|---|
| Challenger: MoH | |||
| High price of drug blocking access | |||
| Year | MNE response | MNE outreach | Outcome |
| 2001 | Price discount if no compulsory license | Compromise | 59% discount |
| 2003 | Offer of voluntary license and price discount | Collaboration and compromise | 25% discount |
| 2005 | Offer of voluntary license and discussions with MoDIT | Collaboration | No voluntary license and no discount |
| 2006-2007 | Lobby with home government | Collaboration and compromise | Issue of compulsory license in 2007 |
| Offer of voluntary license and price discount after announcement of compulsory licence | |||
| Uncertainty trigger: societal | |||
|---|---|---|---|
| Challenger: MoH | |||
| High price of drug blocking access | |||
| Year | MNE response | MNE outreach | Outcome |
| 2001 | Price discount if no compulsory license | Compromise | 59% discount |
| 2003 | Offer of voluntary license and price discount | Collaboration and compromise | 25% discount |
| 2005 | Offer of voluntary license and discussions with MoDIT | Collaboration | No voluntary license and no discount |
| 2006-2007 | Lobby with home government | Collaboration and compromise | Issue of compulsory license in 2007 |
| Offer of voluntary license and price discount after announcement of compulsory licence | |||
Sharing content requires targeting cookies to be enabled. Please update your cookie preferences to use this feature.